At Southern RNA, we provide integrated contract development and manufacturing services designed specifically for RNA therapeutics and vaccine programmes. As an Australian-based mRNA CDMO, we partner with biotechnology companies, research institutes and clinical developers to translate innovation into high-quality, regulatory-ready material.
A confidential biotech partner engaged Southern RNA to support the development of a novel mRNA therapeutic. The project encompassed research and development, GMP-aligned manufacturing, and analytical support, with the goal of advancing the programme from early discovery to first-in-human (FIH) clinical studies.
The client faced a tight timeline to progress their mRNA candidate into FIH trials. They required high-quality, scalable RNA production while maintaining reproducibility, regulatory alignment, and comprehensive analytical verification. Fragmented workflows and limited in-house capacity created a risk of delays and inconsistencies, which could impact clinical readiness.
Southern RNA provided a fully integrated solution, combining construct optimisation, process development, GMP-aligned RNA production, and robust analytical testing. Our platform-based workflow minimised handovers, ensured consistent quality, and maintained traceable, audit-ready documentation. Close collaboration with the client allowed us to align deliverables with programme milestones and regulatory requirements.
